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Black men who have sex with men (MSM) are disproportionately affected by HIV 
in the United States (US). Despite representing less than 1% of the US population, Black 
MSM accounted for the highest number of new HIV diagnoses in 2014. Culturally-
tailored interventions are needed to control the HIV epidemic in this population. The HIV 
Prevention Trials Network (HPTN) 061 study was designed to assess the feasibility of a 
multi-component intervention for reducing HIV incidence among Black MSM. The HPTN 
061 study enrolled 348 HIV-infected men and 1,205 HIV-uninfected men; 28 men 
seroconverted during the study for an annual incidence rate of 3.0% overall and 5.9% 
among younger men (aged 18-30 years). Men in the HPTN 061 study completed 
detailed demographic and behavioral assessments at each study visit, which included an 
evaluation of risk behaviors associated with HIV transmission and acquisition. 
Demographic and behavioral factors that influence HIV transmission and acquisition may 
also impact the characteristics of infecting viral populations and their subsequent 
evolution. The work in this dissertation analyzed factors associated with HIV drug 
resistance, tropism, and genetic diversity in this cohort of Black MSM in the US. These 
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Disparities in the US HIV epidemic among Black MSM 
In the United States (US), the incidence of human immunodeficiency virus (HIV) 
infection has remained relatively stable since the mid-1990’s [1-3]. HIV infects 
approximately 50,000 individuals each year, over half of whom are men who have sex 
with men (MSM) [1-3]. MSM comprise just 2% of the US population. Yet, the US Centers 
for Disease and Control and Prevention (CDC) estimate that MSM represent over half of 
all diagnosed individuals living with HIV in 2011 and half of all individuals who have died 
from acquired immune deficiency syndrome (AIDS) since the start of the HIV epidemic 
[4]. Young MSM (aged 13-29 years) are also the only risk group in the US with a rising 
HIV incidence rate [2]. These numbers highlight the urgency of identifying effective 
interventions for HIV prevention in MSM. 
 Among MSM, Black MSM are most affected by HIV. Black MSM represent 36% 
of new HIV infections among MSM, and approximately half of all new infections among 
young MSM occur in young Black MSM [2, 3]. Despite their elevated HIV incidence, 
Black MSM typically engage in fewer risk behaviors than other MSM. Black MSM report 
less unprotected anal intercourse, less substance use during sex, and lower numbers of 
male sexual partners [5]. Black MSM also participate in more HIV prevention behaviors, 
such as HIV testing, condom use, and disclosure of HIV status to partners [5].  
Recent studies suggest that the high rates of HIV among Black MSM may be the 
result of structural barriers to HIV testing and care [5, 6]. Compared to White MSM with 
HIV infection, HIV-infected Black MSM are less likely to have health insurance and more 
likely to be diagnosed at a lower CD4 cell count [5, 6], which suggests late HIV 
diagnosis. More than half of HIV-infected Black MSM are not aware of their seropositive 
status [7]; therefore, they are not receiving antiretroviral treatment (ART) and are at 
higher risk for transmitting HIV to others. Several studies also indicate that Black MSM 
tend to have same-race sexual partners [5, 8, 9], which may contribute to the high HIV 
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incidence rates among Black MSM when combined with the high prevalence of 
undiagnosed HIV infection. 
 
HPTN 061: The Brothers Study 
Because of the racial disparity of HIV infection in MSM, the HIV Prevention Trials 
Network (HPTN) evaluated the feasibility of a multi-component intervention for reducing 
HIV incidence in Black MSM [10, 11]. The HPTN 061 study is the largest longitudinal 
cohort of Black MSM in the US to date. The study enrolled both HIV-infected men at a 
high risk for HIV transmission and HIV-uninfected men at a high risk for HIV acquisition 
in six US cities between 2009 and 2010. Men were followed for one year, provided 
samples for laboratory testing, and completed detailed behavioral assessments and 
social and sexual network questionnaires. Many of the men enrolled in HPTN 061 were 
poor (annual household income <$10,000) and did not have a college education [11]. 
Nearly a quarter of the men were HIV infected at study enrollment [11]. The majority of 
those men were classified as previously diagnosed by either self-report or antiretroviral 
(ARV) drug testing [12]. Compared to previously-diagnosed men, HIV-infected men who 
were classified as newly diagnosed were more likely to be younger, have sexual 
partners of unknown HIV status, and have multiple sexually transmitted infections (STIs) 
[11]. Compared to HIV-uninfected men, newly-diagnosed men were more likely to be 
unemployed, have unprotected receptive anal intercourse, and have STIs [11]. 
The annual HIV incidence rate in HPTN 061 was 3.0% overall (95% confidence 
interval [CI]: 2.0-4.4%) with the highest HIV incidence among younger men (aged 18-30 
years, 5.9%, 95% CI: 3.6-9.1%) [10]. In addition to younger age, HIV incidence was 
higher among men who reported unprotected receptive anal intercourse with HIV-
positive partners or partners of unknown HIV status. Younger men in HPTN 061 were 
more likely to have STIs during follow-up and have unmet healthcare needs, such as not 
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having a usual place for health care [10]. These findings from HPTN 061 further highlight 
the need for culturally-tailored interventions to increase Black MSM engagement in 
health care, including HIV treatment and prevention, to reduce HIV transmission and 
acquisition. 
 
The HIV life cycle 
 HIV infection is initiated when the virus infects and replicates within CD4+ T cells 
to form infectious viral particles. Cellular HIV replication occurs in stages [13]. First, the 
viral envelope binds to the host cell CD4 receptor. This facilitates conformational 
changes in the viral envelope that allow the virus to bind either the CCR5 or CXCR4 
coreceptor and fuse to the cellular membrane. HIV ribonucleic acid (RNA) and proteins 
are then released into the cytoplasm. The HIV RNA is reverse transcribed into 
deoxyribonucleic acid (DNA) by HIV reverse transcriptase, and a pre-integration 
complex (PIC) forms that contains HIV DNA and viral proteins. The PIC is translocated 
into the nucleus where the HIV DNA is integrated into the host cell DNA by HIV 
integrase. New HIV RNA and viral proteins are transcribed and translated from the 
integrated HIV DNA using host cell machinery. These components are assembled at the 
cellular membrane, and new immature virions form via budding. After budding, HIV 
protease cleaves the structural polyprotein to form mature, infectious viral particles. 
 
HIV treatment and prevention 
 Over 20 ARV drugs have been approved by the US Food and Drug 
Administration (FDA) for HIV treatment to date [14]. These drugs comprise five ARV 
drug classes: entry inhibitors (i.e., coreceptor antagonists and fusion inhibitors), 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), and 
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protease inhibitors (PIs). Each ARV drug class targets a specific step in the HIV life 
cycle. The goal of ART for HIV infection is to drastically reduce cellular HIV replication, 
which is reflected by a decrease in plasma HIV viral load to below the limit of detection 
for clinical assays (<20-400 HIV RNA copies/mL). Individuals who achieve viral 
suppression have better clinical outcomes due to immune restoration (i.e., an increase in 
the number of circulating CD4 cells) [15]. 
Since the mid-1990’s, treatment guidelines have recommended triple ARV drug 
combinations for ART. Triple drug regimens comprised of at least two ARV drug classes 
help combat the development of HIV drug resistance. HIV variants with resistance to 
individual ARV drugs naturally occur before ART initiation [16]. This is due to the high 
genetic diversity of HIV resulting from its large viral population, short viral half-life, error-
prone reverse transcription, and frequent viral recombination [17]. Treatment with a 
single ARV drug rapidly selects for these drug-resistant HIV variants. However, the 
probability that a HIV variant with resistance to three ARV drugs from multiple drug 
classes will naturally occur is much lower [16, 18]. 
ARV drugs can also be used for pre- or post-exposure chemoprophylaxis (PrEP 
or PEP) to prevent HIV infection. The efficacy of chemoprophylaxis for HIV prevention 
was first demonstrated in adults through PEP. In a case-control study of healthcare 
workers after needlestick injury; healthcare workers who took zidovudine (ZDV) alone 
within 72 hours of injury had an 80% lower chance of acquiring HIV [19]. Additional 
studies showed that dual regimens for non-occupational PEP (i.e., after possible HIV 
exposure from sex or injection drug use) were also effective [20, 21]. Current US 
guidelines recommend initiating a triple drug regimen for PEP (similar to ART) within 72 
hours of exposure to bodily fluids from an individual who may be HIV infected [22, 23]. 
PEP studies validated the use of ARV drugs to prevent HIV infection, which led to the 
development of PrEP as an alternative approach for HIV prevention. In 2012, the US 
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FDA approved the use of Truvada® (co-formulated emtricitabine [FTC] and tenofovir 
[TFV] disoproxil fumarate) for PrEP in HIV-uninfected individuals at a high risk for HIV 
acquisition [24]. Taken daily, Truvada can decrease the risk for HIV acquisition among 
HIV-uninfected individuals by more than 90% [25-27]. 
 
HIV drug resistance 
 As mentioned above, drug-resistant HIV variants can naturally arise due to the 
extensive viral diversity of HIV. Prolonged exposure to non-suppressive levels of ARV 
drugs can select for drug-resistant viruses [28], which can paradoxically lower HIV 
diversity if genetic bottlenecking occurs [29]. Individuals can be exposed to non-
suppressive levels of ARV drugs in a variety of settings. In the context of ART, 
individuals may be taking a suboptimal ART regimen or a regimen that includes one or 
more drugs to which they already have resistance. Certain medications and other 
substances can also interfere with ARV drug absorption or activation, or enhance the 
metabolism or clearance of ARV drugs [30]. Non-suppressive levels of ARV drugs may 
also occur in individuals who are non-adherent to ART and in individuals taking ARV 
drugs for PrEP, PEP, or recreational use before knowing they are HIV infected [31-33]. 
HIV drug resistance can lead to treatment failure and limit future treatment 
options. Resistance mutations to one ARV drug also often confer resistance to other 
ARV drugs in the same drug class [28]. Drug-resistant HIV strains can also be 
transmitted to others, which can affect treatment options for newly-infected individuals. 
Transmitted drug resistance (TDR) has been associated with an increased risk for 
virologic failure in patients on ART [34]. Determining the prevalence of HIV drug 
resistance and TDR is important for understanding the current state of the HIV epidemic 
and guiding treatment recommendations. 
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HIV coreceptor tropism can also affect HIV susceptibility to certain ARV drug 
classes. Cellular HIV entry is mediated by the viral envelope, CD4 receptor, and CCR5 
or CXCR4 coreceptors. CCR5 coreceptor antagonists bind to the CCR5 coreceptor to 
prevent cellular HIV entry; currently, the only CCR5 antagonist approved for use in the 
US is maraviroc [14]. HIV tropism is determined by coreceptor usage; viruses can use 
CCR5 exclusively (R5), CXCR4 exclusively (X4), or both coreceptors (dual-tropic). Viral 
populations can be comprised of solely R5 or X4 viruses or include dual/mixed (DM) 
viruses. R5 viruses are susceptible to CCR5 antagonists while X4 viruses are not. 
Consequently, maraviroc use in individuals who have DM viruses may select for X4 and 
dual-tropic viruses [35]. 
 The work in this dissertation characterized HIV drug resistance, tropism, and 
genetic diversity in samples from HIV-infected Black MSM enrolled in the HPTN 061 
study. In particular, this work explored the association of demographic factors and risk 
behaviors with the characteristics of viral populations in these men. These studies 
included men who were HIV infected at study enrollment and men who acquired HIV 
infection (i.e., seroconverted) during the study. Understanding HIV virology in these two 
groups provides new insights into the general HIV epidemic in this population, as well as 
HIV-related issues affecting newly-infected Black MSM. These findings will help guide 
interventions to improve the quality of HIV treatment and prevention among Black MSM 















The samples used in this research were obtained from the HPTN 061 study. 
HPTN 061 (NCT 00951249) was a multi-site study that enrolled 1,553 self-identified 
Black MSM between July 2009 and October 2010 in the US [10, 11]. The study enrolled 
men at eight sites in six cities: Atlanta, GA; Boston, MA; Los Angeles and San 
Francisco, CA; New York City, NY; and Washington, DC. Men were recruited from the 
community (index participants) or were sexual partners referred by index participants; 
men were eligible for the study if they reported having unprotected anal intercourse with 
a man in the six months prior to study enrollment. Index participants were comprised of 
three groups: (1) HIV-uninfected men; (2) HIV-infected men who reported that they were 
unaware of their HIV status (newly diagnosed); and (3) HIV-infected men who reported 
that they were aware of their HIV status (previously diagnosed) [11]. Index participants 
who reported that they were previously diagnosed included men who were at increased 
risk for HIV transmission (defined as not receiving HIV care and having unprotected sex 
with HIV-uninfected partners or partners of unknown HIV status) or decreased risk for 
HIV transmission (defined as being in HIV care or only having unprotected sex with HIV-
infected partners; capped at a maximum of 10 per study site). HPTN 061 study 
participants were followed for one year. Men provided demographic data to an 
interviewer at the enrollment visit and completed a behavioral assessment and social 
and sexual network questionnaire using audio computer-assisted self-interview (ACASI) 
technology at each visit [10, 11]. Plasma samples were stored at each visit for laboratory 
assessments. 
HIV and STI testing were performed at the study sites at enrollment and at the 6- 
and 12-month follow-up visits [10]. HIV screening was performed at the study sites using 
a single HIV rapid test; if the rapid test was reactive, a Western blot was performed at a 
local laboratory. CD4 cell count and HIV viral load were measured for men with HIV 
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infection. Stored plasma samples were tested retrospectively at the HPTN Laboratory 
Center (Johns Hopkins University, Baltimore, MD) for quality assurance, to identify men 
who had acute HIV infection at enrollment, and to confirm cases of HIV seroconversion 
[10, 11]. Enrollment samples from participants with low or undetectable HIV RNA 
(<1,000 copies/mL) who reported they were newly diagnosed were also tested for the 
presence of ARV drugs; men who had ARV drugs detected that were consistent with 
ART were considered previously diagnosed [10-12]. 
 All study participants in HPTN 061 provided written informed consent for 
participation. Each study was approved by institutional review boards at each 
participating institution. 
 
Identification of recent HIV infection 
 Multi-assay algorithms (MAAs) that use a combination of serologic and non-
serologic biomarkers can discriminate between new (recent) HIV infections and non-
recent infections [36-38]. The MAA used in this dissertation identifies recent infections in 
clade B HIV populations using two serologic assays (the BED-capture enzyme 
immunoassay [BED-CEIA] and an avidity assay) and two non-serologic biomarkers 
(CD4 cell count and HIV viral load) [36, 38]. Clade B is the predominant HIV subtype in 
the US [39]. Men in HPTN 061 were classified as recently infected if they had a CD4 cell 
count >50 cells/mm, a BED-CEIA <1.6 normalized optical density units, an avidity index 
<85%, and a HIV viral load >400 copies/mL. The window period for recent infection 
using this MAA is 159 days (95% CI: 134-186 days) [37]. 
 
Detection of ARV drugs 
A rapid, high-throughput ARV drug assay was used to test samples for the 
presence of 15 ARV drugs: four NRTIs (FTC, TFV, ZDV, and lamivudine [3TC]); two 
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NNRTIs (efavirenz [EFV] and nevirapine [NVP]), and nine PIs (atazanavir [ATV], 
amprenavir [APV], darunavir [DRV], indinavir [IDV], lopinavir [LPV], nelfinavir [NFV], 
saquinavir, tipranavir, and ritonavir [RTV]). Plasma samples were prepared by combining 
100 µL plasma with 300 µL acetonitrile containing 125 ng/mL deuterated morphine-d3. 
The resulting supernatant was dried and reconstituted with 150 µL water. ARV drugs 
were detected using high-performance liquid chromatography coupled with high-
resolution accurate mass-mass spectrometry (Exactive-Orbitrap; Thermo Scientific, 
Pittsburgh, PA). The mobile phase system consisted of 10 mM ammonium acetate and 
0.1% ammonium hydroxide in methanol. Samples were introduced onto a 1.9-µm 
Hypersil Gold perfluorinated phenyl column at 100% aqueous composition; elution 
occurred during a 3.25 minute step-and-hold isocratic step to 100% methanol. Positive 
full-ion MS and all-ion fragmentation were conducted at 100,000 and 25,000 resolution, 
respectively; negative full-ion MS was conducted at 100,000 resolution. ZDV and EFV 
were detected using parent-ion scanning in negative ion mode and fragment 
identification in positive ion mode. All other ARV drugs were analyzed in positive ion 
mode for both the parent and fragment ions. The limit of identification for all 15 ARV 
drugs in this assay was 10 ng/mL. 
 
Detection of HIV drug resistance mutations 
 The ViroSeq HIV-1 Genotyping System (Celera Diagnostics, Alameda, CA) is a 
population (bulk) sequencing method that generates a consensus sequence that can be 
used to analyze HIV drug resistance mutations (DRMs) associated with three ARV drug 
classes: NRTIs, NNRTIs, and PIs. The ViroSeq System reliably detects mutations 
present in more than 20% of the viral population [40, 41], but can detect some mutations 





ViroSeq HIV-1 Genotyping System 
 HIV RNA was isolated from 500 µL of plasma, purified, and resuspended in 50 
µL RNA diluent. Moloney murine leukemia virus reverse transcriptase and a single 
primer were used to reverse transcribe 10 µL HIV RNA into complementary DNA 
(cDNA), and a 1.8 kb region of HIV pol was amplified from the cDNA by polymerase 
chain reaction (PCR). A nested PCR was performed for samples with low HIV viral loads 
that failed to amplify using the standard procedure [43]. The resulting PCR product was 
quantified, purified, and diluted to an optimized concentration for sequencing. Samples 
were sequenced using seven primers (four forward and three reverse) and standard 
dideoxy chain termination using an Applied Biosystems 3130xl Genetic Analyzer (Life 
Technologies Corporation, Grand Island, NY). Sequences from each sample were 
assembled into a 1.3 kb consensus sequence and compared to a reference sequence to 
identify mutations using the ViroSeq HIV-1 Genotyping Software, v2.8. The 1.3 kb 
consensus sequence includes the coding regions for all of HIV protease and 
approximately two-thirds of HIV reverse transcriptase (codons 1-335). HIV drug 
resistance to NRTIs, NNRTIs, and PIs was predicted using the ViroSeq Algorithm 
Advisor included in the software package. 
 
ViroSeq HIV-1 Integrase Genotyping Kit 
 The ViroSeq HIV-1 Integrase Genotyping Kit (Celera Diagnostics, Alameda, CA) 
uses HIV RNA prepared by the ViroSeq HIV-1 Genotyping System; the kit is for research 
use only. A 1.1 kb amplicon of HIV integrase was amplified using a one-step reverse 
transcription-PCR (RT-PCR) with Omniscript and Sensiscript reverse transcriptases and 
10 µL HIV RNA. The resulting PCR product was quantified, purified, and diluted to an 
optimized concentration for sequencing. Samples were sequenced using four primers 
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(two forward and two reverse) and standard dideoxy chain termination using an Applied 
Biosystems 3130xl Genetic Analyzer. Sequence data from each sample were 
assembled into a 0.9 kb consensus sequence and compared to a reference sequence to 
identify mutations using the ViroSeq Integrase Software, v1.0. The 0.9 kb consensus 
sequence includes all of HIV integrase. HIV drug resistance to INSTIs was predicted 
using the ViroSeq Algorithm Advisor included in the software package. 
 
Prediction of rilpivirine resistance 
 HIV drug resistance to rilpivirine, a NNRTI, was predicted using the HIV reverse 
transcriptase consensus sequence (codons 1-335) generated by the ViroSeq HIV-1 
Genotyping System. Consensus sequences were manually analyzed for rilpivirine-
associated DRMs included in the ViroSeq Algorithm Advisor for the ViroSeq HIV-1 
Genotyping Software, v3.0 (Celera Diagnostics, Alameda, CA). Rilpivirine resistance 
was predicted according to the ViroSeq Algorithm Advisor criteria. 
 
Determination of HIV coreceptor tropism 
  The Trofile assay (Monogram BioSciences, San Francisco, CA) is a clinically-
validated, phenotypic tropism assay, which can distinguish HIV coreceptor usage for HIV 
variants present in 0.3% of the viral population [44]. Full-length env sequences from 
each sample were amplified and cloned into expression vectors [44, 45]. Pseudoviruses 
were prepared by cotransfecting human embryonic kidney cell cultures with the env 
expression vectors and a replication-defective HIV genomic vector containing a 
luciferase reporter gene. HIV coreceptor tropism was determined by infecting CCR5+ 
and CXCR4+ cells in the presence and absence of CCR5 and CXCR4 inhibitors. Viral 
replication was quantified by measuring luciferase activity (reported as relative light 
units, which reflect the level of luciferase activity). Analysis of individual viral variants 
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(clonal analysis) was also performed at Monogram BioSciences using samples from 
seroconverters who had DM viruses. HIV tropism was determined for 16-20 env clones 
from the viral populations of each individual. In addition, the V3 loop of each clone was 
sequenced using standard dideoxy-chain termination [46]. 
 
Measurement of HIV diversity 
 Our research group developed a high resolution melting (HRM) diversity assay 
that can quantify HIV diversity as a single numeric HRM score without sequencing [47, 
48]. The HRM scores generated by the assay are highly correlated with sequence-based 
diversity measures [47, 49]. 
 
Preparation of DNA templates for the HRM diversity assay 
 HIV DNA used to analyze HIV gag and pol was generated using the ViroSeq 
HIV-1 Genotyping System. The diluted PCR products used for sequencing were diluted 
1:10 for HRM analysis [47]. HIV DNA used to analyze HIV env was generated using the 
QIAGEN OneStep RT-PCR Kit (QIAGEN, Valencia, CA) and HIV RNA prepared by the 
ViroSeq HIV-1 Genotyping System. A 0.7 kb amplicon of HIV env was amplified using 
Omniscript and Sensiscript reverse transcriptases, 10 µL HIV RNA, and a forward 
(JH35F: 5’-TGARGGACAATTGGAGAARTGA-3’) and reverse (JH38R: 5’-
GGTGARTATCCCTKCCTAAC-3’) primer [48]. The resulting PCR product was 
quantified and diluted to an optimized concentration for additional analysis. ExoSap-IT 
(United States Biochemical Corporations, Cleveland, OH) was then used to purify 5 µL 
of the diluted PCR product. The purified PCR product was added to 45 µL 





HRM diversity assay and DivMelt analysis 
 The HRM diversity assay was performed for six regions of the HIV genome: two 
in gag (GAG1 and GAG2), one in pol (POL), and three in env (ENV1, ENV2, and ENV3, 
Table 2.1) [47, 48]. Amplicons for each region were generated using 1 µL 1:10 diluted 
and purified PCR product, forward and reverse primers, and 1x LightScanner Master Mix 
amplification buffer (Idaho Technology, Salt Lake City, UT). The LightScanner Master 
Mix includes Taq polymerase and LCGreen Plus dye, which is incorporated into the 
amplicons. The resulting amplicons were melted using the LightScanner Instrument 
(Model HR 96, Idaho Technology, Salt Lake City, UT) at a melting range of 68-98°C with 
a 65°C hold (for GAG1, GAG2, and POL amplicons) or 60-98°C with a 57°C hold (for 
ENV1, ENV2, and ENV3 amplicons). Melting data for each amplicon were processed 
using the LightScanner software (Idaho Technology, Salt Lake City, UT) to generate 
melting curves that represent the negative derivative of the fluorescence vs. temperature 
(-dF/dT). 
 Melting curves were analyzed using the DivMelt software package, version 1.0.2 
[50] in R, version 2.14.1 (The R Foundation for Statistical Computing, Vienna, Austria). 
The width of the melting peak corresponds to the HRM score (i.e., the output of the HRM 
diversity assay). Region-specific DivMelt analysis protocols were used. 
 
Statistical methods 
 All statistical analyses were performed by the HPTN Statistical and Data 
Management Center (Fred Hutchinson Cancer Research Center, Seattle, WA). Details 




Table 2.1. HRM regions analyzed using the HRM diversity assay. 
Region HXB2 coordinatesa HIV genomic regiona Primer Sequences 
GAG1 1998-2097 gag p7 and p1 Forward: 5’-AAATTGCAGGGCCCCTAGGAA-3’ 
   Reverse: 5’-TTTCCCTAAAAAATTAGCCTGTCT-3’ 
GAG2 2068-2278 gag p1 and p6; pol transframe Forward: 5’-ACTGAGAGACAGGCTAATTTTTTAG-3’ 
   Reverse: 5’-GGTCGTTGCCAAAGAGTGATTTG-3’ 
POL 2373-2597 pol protease and reverse transcriptase Forward: 5’-AAATGGAAACCAAAAATGATAG-3’ 
   Reverse: 5’-CATTCCTGGCTTTAATTTTACTG-3’ 
ENV1 7798-8036 env gp41 heptad repeat 1 Forward: 5’-CAGCAGGWAGCACKATGGG-3’ 
   Reverse: 5’-GCARATGWGYTTTCCAGAGCADCC-3’ 
ENV2 7950-8119 env gp41 immunodominant region Forward: 5’-CTYCAGRCAAGARTCYTGGC-3’ 
   Reverse: 5’-TCCCAYTSCAKCCARGTC-3’ 
ENV3 8016-8299 env gp41 heptad repeat 2 Forward: 5’-TGCTCTGGAAARCWCATYTGC-3’ 
   Reverse: 5’-AARCCTCCTACTATCATTATRA-3’ 
 
Legend for Table 2.1. 
Abbreviations: HRM: high resolution melting. 
a Each HRM amplicon corresponds with the genomic coordinates listed for HXB2 and portions of the genomic regions that encode for 
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Introduction 
HPTN 061 provided important information about the HIV epidemic in Black MSM. 
By design, most of the HIV-infected men enrolled in HPTN 061 reported that they were 
unaware of their HIV status (newly diagnosed) or that they were aware of their status 
(previously diagnosed) but were not in care [11]. However, 54% of the HIV-infected men 
who reported that they were newly diagnosed had low or undetectable HIV viral loads at 
study enrollment. Although none of these men reported prior or current ARV drug use, 
ARV drug testing revealed that 78% of these men were taking ARV drugs consistent 
with ART, but chose not to disclose this to study staff [12]. Some men had unusual 
patterns of ARV drugs detected (e.g., two NNRTIs, a NNRTI with a PI, or multiple PIs). A 
few men had one or two NRTIs detected in the absence of an NNRTI or PI, which 
suggested that they may have been using ARV drugs for PrEP or PEP [12]. ARV drugs 
were also detected in some men with low but detectable HIV viral loads (400-1,000 
copies/mL). This was concerning, since exposure to non-suppressive levels of ARV 
drugs promotes selection of HIV with DRMs [28], which can be transmitted to others. 
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These findings indicated the need for further evaluation of ARV drug use and HIV drug 
resistance among Black MSM in the HPTN 061 cohort.  
 This chapter presents a comprehensive analysis of ARV drug use and HIV drug 
resistance among HIV-infected men in the HPTN 061 cohort who were not virally 
suppressed. By combining ARV drug testing with HIV genotyping, it was possible to 
assess levels of drug resistance, the risk for increasing drug resistance, and patterns of 
ARV drug use in this cohort. Inclusion of ARV drug testing in these assessments, rather 
than relying solely on self-reported ARV drug use, also provided a more accurate 




HIV genotyping was performed retrospectively using plasma samples from men 
who had viral loads >400 copies/mL, including men who were HIV infected at study 
enrollment and men who seroconverted during the study. All men were asked about 
ARV drug use for PrEP or PEP at their study visits; men were also asked about prior or 
current ART. 
 
GenBank accession numbers: KM357930-KM358121. 
 
Statistical methods 
Fisher’s exact and chi-square tests were used for univariate analyses. Correlates 
of HIV drug resistance, multi-class drug resistance (MCR), and ARV drug detection were 
also compared among men who were included in this sub-study (those with HIV 
genotyping results) vs. men who were not included in this sub-study (those with viral 
suppression). Multivariate analyses were attempted via generalized linear mixed models 
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but had inadequate power for modeling the site-to-site variability among covariates. All 
statistical analyses were performed using SAS, version 9.2 (SAS Institute, Cary, NC). 
 
Results 
Analysis of HIV-infected men at study enrollment 
Study cohort 
In HPTN 061, 348 men were HIV infected at enrollment; 163 were virally 
suppressed (viral load ≤400 copies/mL) and 14 men refused further testing or had no 
sample available. The remaining 171 men had HIV viral loads >400 copies/mL; 
genotyping was successful for 169 of those men (men included in this sub-study). 
Eighty-one (48%) of the 169 men reported that they were newly diagnosed and 88 (52%) 
reported that they were previously diagnosed; 31 (35%) of the 88 men reported that they 
were in HIV care. Demographic and behavioral characteristics of the 169 men are shown 
in Table 3.1. Compared to the 163 HIV-infected men who were virally suppressed and 
not included in this sub-study, the 169 men included in this sub-study were more likely to 
be younger than 30 years old (P<0.001) and were less likely to have reported prior or 
current ART at study enrollment (P=0.004 and P<0.001, respectively).  
 
HIV drug resistance 
 At least one DRM was detected in 48 (28%) of the 169 men (Table 3.1). 
Nineteen (11%) of the men had MCR, including two (1%) who had HIV that was resistant 
to all three ARV drug classes (NRTIs, NNRTIs, and PIs). NNRTI-associated DRMs were 
most common, followed by NRTI- and PI-associated DRMs; the most prevalent DRMs 
were K103N/S and M184V/I. In univariate analyses, older age (>30 years), reporting 
being in HIV care, and reporting prior or current ART use were significantly associated 
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with any HIV drug resistance and with MCR; MCR was also more common among men 
who reported having no or one sexual partner in the previous six months (Table 3.1). 
 
ARV drug detection 
None of the men reported ARV drug use for PrEP, and only one reported ARV 
drug use for PEP. Twenty-one of the 139 men who were asked about ART reported both 
prior and current ART (30 of the newly-diagnosed men were not asked about ART); 11 
men reported prior ART only. At least one ARV drug was detected in samples from 60 
(36%) of the 169 men (Table 3.2); 42 (70%) of the 60 men reported no prior or current 
ARV drug use. ARV drug detection was associated with reporting prior or current ART 
(P=0.02 and P=0.03, respectively), but was not associated with any of the other 
demographic or behavioral factors shown in Table 3.1 (data not shown). 
NRTIs and PIs were the most frequently detected ARV drug classes, and FTC 
was the most frequently detected ARV drug (Figure 3.1). Thirty-one (52%) of the 60 men 
had ARV drugs detected that were consistent with treatment regimens that are currently 
recommended or were recommended at the time of study enrollment (2009-2010) by the 
US Department of Health and Human Services (Table 3.2) [51-53]. Because the half-life 
of NRTIs is shorter than the half-life of NNRTIs and PIs, detection of a PI or NNRTI 
alone was considered to be consistent with recommended ART if the PI or NNRTI was 
included in one of the recommended treatment regimens. Detection of ARV drugs that 
were consistent with a recommended treatment regimen was more frequent among men 
who reported that they were previously diagnosed (regardless of whether they reported 
that they were in care) than among men who reported that they were newly diagnosed 
(68% vs. 31%, P=0.009). 
The remaining 29 men had ARV drugs or combinations of drugs detected that 
are not consistent with recommended treatment regimens (Table 3.2). NFV was 
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detected in 13 men (7 had NFV alone) and IDV was detected in 2 men (one had IDV 
alone); these drugs were no longer recommended for treatment at the time the HPTN 
061 study was performed. Thirteen men had a single NRTI detected (nine had ZDV, 
three had FTC, and one had TFV). Detection of a single NRTI or other ARV drugs and 
drug combinations that were not consistent with recommended ART was more common 
among men who reported no prior HIV diagnosis than among men who reported that 
they were previously diagnosed (69% vs. 32%, P=0.009). 
 
Relationship between HIV drug resistance and ARV drug detection 
We next evaluated the relationship between HIV drug resistance and ARV drug 
use in the 48 men who had drug-resistant HIV at enrollment (Figure 3.1). ARV drugs 
were more frequently detected in these 48 men than in the 121 men without drug 
resistance (56% vs. 27%, P<0.001). Men with drug-resistant HIV were more likely to 
have NRTIs and PIs detected (P=0.001 and P<0.001, respectively), including FTC 
(P<0.001), TFV (P=0.01), 3TC (P=0.002), RTV (P<0.001), ATV (P=0.01), and LPV 
(P=0.02). Among the 48 men who had drug-resistant HIV, 18 (38%) had at least one 
ARV drug detected that was not consistent with the DRMs detected, indicating that they 
were at risk of acquiring additional DRMs. The data obtained from ARV drug testing was 
also used to estimate the rate of TDR. When the rate of TDR was based solely on the 
frequency of DRMs among the 137 men who reported no prior or current ARV drug use 
(i.e., based solely on self-report of ARV drug use), the estimated rate of TDR was 23%. 
When 14 men with DRMs who also had ARV drugs detected (i.e., when ARV drug 
testing was used in addition to self-report of ARV drug use) were excluded, the 
estimated rate of TDR was only 12%. Five (29%) of the 17 men who were classified as 




Analysis of newly-infected men 
Study cohort 
Thirty-nine men in this sub-study were classified as newly infected: three had 
acute HIV infection at study enrollment, 13 had recent HIV infection at study enrollment 
(identified using a MAA [37]), and 23 seroconverted during the HPTN 061 study [10]. 
The 23 seroconverters had a median viral load of 36,078 copies/mL (interquartile range: 
5,933 to 85,140 copies/mL) at the first HIV-positive visit. Five additional seroconverters 
in HPTN 061 were not included in this sub-study (one did not have sufficient sample 
available from the first HIV-positive visit, and four had viral loads ≤400 copies/mL [54]).  
 
HIV drug resistance 
DRMs were detected in nine (23%) of the 39 newly-infected men. No DRMs were 
detected in any of the acutely-infected men. The NNRTI-associated K103N/S mutation 
was detected in four (31%) of the 13 recently-infected men and four (17%) of the 23 
seroconverters (one of whom also had the NNRTI-associated P225H mutation); one 
additional seroconverter had the PI-associated L90M mutation. 
 
ARV drug detection 
Ten (26%) of the 39 newly-infected men had at least one ARV drug detected. 
ARV drugs were detected in one (33%) of the three acutely-infected men (NFV and 
ZDV) and nine (69%) of the 13 recently-infected men (three with NFV, two of whom had 
the K103N mutation; five with ZDV and one with NVP, none of whom had DRMs). No 
ARV drugs were detected in samples from the seroconverters at the first HIV-positive 






In HPTN 061, 48 (28%) of the HIV-infected men who were not virally suppressed 
had drug-resistant HIV at study enrollment and 11% had MCR. HIV drug resistance and 
MCR were associated with older age, reporting being in HIV care, and reporting prior or 
current ART. A novel, high-throughput, multi-drug assay was used to assess ARV drug 
use in this cohort. ARV drug testing identified many men who were at risk for acquiring 
additional DRMs. At least one ARV drug was detected in 27% of the men who did not 
have drug-resistant HIV, and 38% of the men who had drug-resistant HIV had at least 
one ARV drug detected that was not associated with their pattern of drug resistance. 
ARV drug testing also revealed that some men were using ARV drugs that were no 
longer recommended for HIV treatment (e.g., NFV and IDV) and that some men had 
unusual patterns of ARV drug use. ARV drug testing also provided a more accurate 
estimate of the rate of TDR. The estimated rate of TDR in this cohort was 23% when 
calculated based solely on the rate of drug resistance among men who reported no prior 
or current ARV drug use. When the results of ARV drug testing were taken into account, 
the estimated rate of TDR was 12%, which is similar to that reported in other recent, 
multi-city US studies [55-58]. This should be considered a maximum estimate of TDR, 
since some men may have taken ARV drugs in the past that were not detected in their 
samples. It is notable that 29% of the men classified as having TDR had MCR. 
ARV drugs were also detected in 10 (26%) of 39 newly-infected men. This group 
included acutely-infected men, recently-infected men (identified with a MAA), and 
seroconverters [10, 11, 37]. Most of these men had NFV or ZDV alone detected. Neither 
of these drugs is currently recommended as part of first-line regimens for PrEP, PEP, or 
ART [22-24, 51]. HIV drug resistance was detected in nine (23%) of the newly-infected 
men; eight had the K103N/S mutation. The prevalence of drug resistance among these 
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men is higher than the prevalence of drug resistance in other studies of newly-diagnosed 
or recently-infected MSM in the US [56, 58]. 
None of the men in this sub-study reported PrEP use, and only one reported PEP 
use. The first reports of successful use of co-formulated FTC/TFV for PrEP appeared in 
2010 [25], after enrollment in HPTN 061 ended. In 2012, Truvada® was approved by the 
US FDA for PrEP in high-risk populations [24]. While this report only included HIV-
infected men, some men may have been using PrEP or PEP if they were not aware of 
their HIV status. In this sub-study, FTC was the most frequent ARV drug detected; TFV 
was also detected in some men. M184V/I, which confers resistance to FTC and other 
NRTIs, was the second most common DRM detected in this cohort; this mutation 
increases susceptibility to TFV [28]. K65R, which is associated with resistance to FTC 
and TFV [28], was detected in only one man. These results are relevant to expanded 
use of Truvada for PrEP among MSM at high risk for HIV acquisition. 
Most studies of HIV drug resistance among MSM in the US have focused on men 
who were failing ART [59, 60], reported they were newly diagnosed [55-57], or were 
recently infected [57, 58, 61-63]. HPTN 061 enrolled both HIV-uninfected and HIV-
infected self-identified Black MSM, including men who reported that they were in care 
[10, 11]. This sub-study (which included men with viral loads >400 copies/mL) and our 
previous report (which included men with low or undetectable HIV viral loads [12]) 
demonstrate that many men in HPTN 061 chose not to disclose that they were using 
ARV drugs. Although other studies from both clinical and research settings have also 
reported undisclosed ARV drug use [64-66], the frequency of undisclosed ARV drug use 
was considerably higher in the HPTN 061 cohort than in other studies. Men may have 
not disclosed past or current ARV drug use because of concerns that it would impact 
their eligibility for the HPTN 061 study. The study also included monetary incentives and 
medical services that may have also contributed to nondisclosure due to the high 
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poverty levels in this cohort [10, 11]. These findings emphasize the benefit of using 
objective, biomedical measures to supplement self-reported data on ARV drug use. 
This study had the following limitations. First, HIV drug resistance testing was 
performed using a method based on population sequencing; DRMs present at low levels 
may not have been detected. Previous studies have shown that minority HIV variants 
with DRMs can impact ART outcomes [67] and that resistance rates may be 
underestimated if these minority variants are not taken into account [68]. Second, only 
resistance and ARV drug use for NRTIs, NNRTIs, and PIs was assessed. Resistance to 
and use of other ARV drug classes, such as entry inhibitors and INSTIs, were not 
assessed. Entry inhibitors and INSTIs are used for ART [51], and INSTIs are also 
recommended for PEP [22]. Therefore, the prevalence of HIV drug resistance and ARV 
drug use in the HPTN 061 cohort may be even higher than reported here. 
The results in this report should be considered in the context of the evolving 
landscape of ARV drug use. Unusual patterns of ARV drug use were detected in this 
sub-study and in our previous report [12]. ARV drugs were also detected in 26% of the 
newly-infected men. In many cases, the reason for ARV drug use could not be 
determined. In addition to ARV drug use for PrEP, PEP, and ART, some men in the 
HPTN 061 cohort may have been using ARV drugs for other reasons. For example, 3TC 
and TFV are recommended by the US FDA for treating chronic hepatitis B virus infection 
[69], and recent reports suggest that ARV drugs may be useful for treating other 
conditions [70]. ARV drugs, such as EFV and RTV, are also used for recreational 
purposes [32, 71, 72]. Increasing evidence also suggests that ARV drugs are shared or 
channeled into illicit markets in some settings, which could compromise ART adherence 
and expanded use of PrEP [71, 73, 74]. More research is needed to understand how 
Black MSM acquire and use ARV drugs. The high rate of undisclosed ARV drug use 
among men in HPTN 061 and other recent reports of undisclosed ARV drug use should 
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HIV drug resistance to rilpivirine and INSTIs 
 
Introduction 
In the previous study, HIV drug resistance to NRTIs, NNRTIs, and PIs was 
frequently detected in the HPTN 061 cohort using the ViroSeq HIV-1 Genotyping 
System, v2.8. This version of the ViroSeq System does not predict resistance to newer 
ARV drugs, such as the NNRTI rilpivirine, and is not designed to analyze HIV drug 
resistance to additional ARV drug classes, such as INSTIs. In the US, rilpivirine and 
INSTIs are now recommended for ART [51] and are also being evaluated for PrEP [75, 
76]. Rilpivirine was not approved by the US FDA for ART until 2011 [14], after enrollment 
in HPTN 061 ended. However, men in HPTN 061 may have DRMs selected by other 
NNRTIs that also confer resistance to rilpivirine. In contrast, raltegravir, the first INSTI, 
was approved by the US FDA for ART in 2007 [14], before enrollment in HPTN 061 
began. The prevalence of rilpivirine and INSTI resistance, particularly among MSM, is 
not well characterized. In this study, rilpivirine and INSTI resistance were analyzed 
among HIV-infected men in HPTN 061, including men who were HIV infected at study 
enrollment and men who seroconverted during the study. 
 
Methods 
Samples from men who had viral loads >400 copies/mL at their enrollment or 
seroconversion visit were analyzed. The analysis of rilpivirine resistance included all 169 
men who were HIV infected at enrollment and 23 seroconverters who were analyzed in 
the previous study. Testing for INSTI resistance was performed using HIV RNA samples 
leftover from the previous study. The analysis of INSTI resistance included 141 men who 






 Two (1%) of the 169 men who were HIV infected at enrollment had HIV 
genotypes that predicted resistance to rilpivirine. Both men also had resistance to 
NRTIs, NNRTIs, and PIs. None of the seroconverters had rilpivirine resistance. 
 
INSTI resistance 
Genotyping results for HIV integrase were obtained for 134 (95%) of the 141 men 
who were HIV infected at enrollment and for 23 seroconverters. None of the men had 
HIV genotypes that predicted resistance to raltegravir, dolutegravir, or elvitegravir. Ten 
(8%) of the men who were HIV infected at enrollment and two (9%) of the 
seroconverters had one or two accessory or polymorphic mutations detected that are 
associated with INSTI resistance. The most frequently detected mutation was E157Q, 




Although NRTI, NNRTI and PI resistance were frequently observed in this cohort 
in the previous study, rilpivirine resistance was only detected in two men and INSTI 
resistance was not detected. The INSTI-associated DRMs that were detected in this 
study were not sufficient to cause INSTI resistance and are most likely viral 
polymorphisms. These results are promising, since INSTIs are now recommended in 
first-line ART regimens in the US [51] and both rilpivirine and INSTIs are under 
evaluation for use as PrEP agents [75, 76]. New INSTIs are also under development for 




Table 3.1. Association between HIV drug resistance and demographic and behavioral factors. 
   Any resistance  Multi-class resistance  
  Total Yes No  Yes No  
Characteristic  169 48 (28%) 121 (72%) P value 19 (11%) 150 (89%) P value 
Age ≤ 30 years 47 (28%) 7 (15%) 40 (85%) 0.02 0 (0%) 47 (100%) 0.002 
 > 30 years 122 (72%) 41 (34%) 81 (66%)  19 (16%) 103 (84%)  
Household income ≤ $30,000/year 131 (78%) 35 (27%) 96 (73%) 0.37 15 (11%) 116 (89%) 1.00 
 > $30,000/year 38 (22%) 13 (34%) 25 (66%)  4 (11%) 34 (89%)  
Employment status Employed 32 (19%) 9 (28%) 23 (72%) 0.97 4 (13%) 28 (88%) 0.76 
 Unemployed 137 (81%) 39 (28%) 98 (72%)  15 (11%) 122 (89%)  
Student Student 31 (18%) 11 (35%) 20 (65%) 0.33 5 (16%) 26 (84%) 0.35 
 Non-student 138 (82%) 37 (27%) 101 (73%)  14 (10%) 124 (90%)  
Health insurance Yes 105 (62%) 32 (30%) 73 (70%) 0.44 14 (13%) 91 (87%) 0.32 
 No 64 (38%) 16 (25%) 48 (75%)  5 (8%) 59 (92%)  
In HIV carea Yes 31 (18%) 15 (48%) 16 (52%) 0.006 9 (29%) 22 (71%) <0.001 
 No 138 (82%) 33 (24%) 105 (76%)  10 (7%) 128 (93%)  
Education High school or less 93 (55%) 26 (28%) 67 (72%) 0.89 7 (8%) 86 (92%) 0.09 
 At least some college 76 (45%) 22 (29%) 54 (71%)  12 (16%) 64 (84%)  
Substance useb Yes 84 (51%) 25 (30%) 59 (70%) 0.62 8 (10%) 76 (90%) 0.72 
 No 80 (49%) 21 (26%) 59 (74%)  9 (11%) 71 (89%)  
 Not available 5 2 3  2 3  
Number of male partnersc 0-1 33 (20%) 11 (33%) 22 (67%) 0.48 8 (24%) 25 (76%) 0.008 
 >1 136 (80%) 37 (27%) 99 (73%)  11 (8%) 125 (92%)  
Prior ARTd Yes 32 (19%) 17 (53%) 15 (47%) 0.001 9 (28%) 23 (72%) 0.001 
 No 107 (63%) 27 (25%) 80 (75%)  10 (9%) 97 (91%)  
Current ARTd Yes 21 (12%) 13 (62%) 8 (38%) <0.001 8 (38%) 13 (62%) <0.001 
 No 148 (88%) 35 (24%) 113 (76%)  11 (7%) 137 (93%)  
City Atlanta 30 (18%) 5 (17%) 25 (83%) 0.01 3 (10%) 27 (90%) 0.09 
 Boston 14 (8%) 7 (50%) 7 (50%)  1 (7%) 13 (93%)  
 Los Angeles 41 (24%) 17 (41%) 24 (59%)  8 (20%) 33 (80%)  
 New York City 50 (30%) 10 (20%) 40 (80%)  2 (4%) 48 (96%)  
 San Francisco 10 (6%) 5 (50%) 5 (50%)  3 (30%) 7 (70%)  




Legend for Table 3.1. 
P values <0.05 are bolded. Abbreviations: ART: antiretroviral treatment. 
a Enrollment of men who reported that they were in HIV care was capped at 10 per study site. 
b Substance use included: inhaled nitrates, smoked and power cocaine, methamphetamine, heroin, non-prescription drug use 
(Oxycontin, Vicodin, or Xanax), or any other hallucinogens. 
c Surveys administered at enrollment included questions about activities in the previous six months. 
d Thirty-two men reported prior and/or current antiretroviral  drug use; all of these men reported a prior HIV diagnosis, and 19 
reported that they were in HIV care at the time of study enrollment. Thirty men who reported being newly diagnosed were not 
asked about prior ART.
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ARV drug(s) detected 60 34 26 
Consistent with recommended ARTb 31 (52%) 23 (68%) 8 (31%) 
Consistent with PI-based regimen 24 18 6 
PI alone (ATV, LPV, DRV, or RTV) 8 6 2 
PI (ATV, LPV, or DRV) ± RTV + NRTI(s)c 16 12 4 
Consistent with NNRTI-based regimen 7 5 2 
NVP alone 3 2 1 
EFV alone 1 1 - 
EFV + FTC 3 2 1 
    
Not consistent with recommended ARTd 29 (48%) 11 (32%) 18 (69%) 
ZDV alone 9 1 8 
NFV alone 7 3 4 
FTC alone 3 3 - 
TFV alone 1 1 - 
IDV alone 1 - 1 
FTC/TFV 1 - 1 
3TC + NFV 1 1 - 
ZDV + NFV 1 - 1 
NVP + APV 1 - 1 
FTC/TFV + NFV 1 1 - 
FTC/TFV + NFV + IDV 1 - 1 
FTC/TFV + NFV + LPV + RTV 1 - 1 
FTC/TFV + NFV + LPV + RTV + ZDV 1 1 - 
 
Legend for Table 3.2. 
Abbreviations: ARV: antiretroviral; ART: antiretroviral treatment; ATV: atazanavir; LPV: lopinavir; 
DRV: darunavir; RTV: ritonavir; NVP: nevirapine; EFV: efavirenz; FTC: emtricitabine; ZDV: 
zidovudine; NFV: nelfinavir; TFV: tenofovir; IDV: indinavir; 3TC: lamivudine; APV: amprenavir. 
a Men were asked whether they were aware of their HIV status at the time of study enrollment. 
b Criteria used to characterize ARV drugs as consistent with recommended ART are described 
in the text. 
c The NRTIs detected were either FTC alone or with TFV, or 3TC.  
d This category includes patterns of ARV drug detection that were not consistent with 
recommended ART regimens. Drugs that were not recommended as part of PrEP, PEP, or 









Legend for Figure 3.1. 
The figure shows the frequency that specific antiretroviral drugs were detected in samples from men who were tested for HIV drug 
resistance. Fisher’s exact and chi-square tests were used to compare the proportion of men who did vs. did not have HIV drug 
resistance (any resistance, defined as detection of at least one DRM). P values for these comparisons are indicated (*P<0.05; 
**P<0.01; ***P<0.001). Abbreviations: ARV: antiretroviral; NRTI: nucleoside/nucleotide reverse transcriptase inhibitor; FTC: 
emtricitabine; TFV: tenofovir; ZDV: zidovudine; 3TC: lamivudine; PI: protease inhibitor; RTV: ritonavir; ATV: atazanavir; NFV: 
nelfinavir; LPV: lopinavir; DRV: darunavir; IDV: indinavir; APV: amprenavir; NNRTI: non-nucleoside reverse transcriptase inhibitor; 
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Introduction 
Individuals with X4/DM viruses often exhibit accelerated disease progression [77, 
78]. While R5 viruses usually predominate early in infection, X4/DM viruses have been 
documented in up to 20% of recently-infected individuals [77, 79-81]. The predominance 
of R5 viruses during primary HIV infection is thought to result from selective advantages 
that favor transmission and/or replication of R5 strains [82]. The prevalence of X4/DM 
viruses in recent infection is higher among people who inject drugs than among those 
with sexually-acquired HIV infection [78, 79, 83]. This suggests that the absence of a 
mucosal barrier may facilitate transmission of X4/DM strains. Sexual practices (e.g., 
insertive vs. receptive intercourse among MSM) may also differentially impact 
transmission of X4/DM viruses. These issues are relevant to HIV prevention efforts, 
since the CCR5 coreceptor antagonist, maraviroc, is being evaluated for use in PrEP 
[84, 85]. 
This report explored whether sexual practices were associated with coreceptor 
tropism in HPTN 061. HIV tropism was analyzed for the subset of study participants in 
HPTN 061 who were HIV infected at enrollment and reported either exclusive insertive 
intercourse or exclusive receptive intercourse, and among men who seroconverted 






 Study participants were asked to provide detailed information on sexual practices 
via ACASI. Insertive intercourse was defined as insertive vaginal or anal intercourse with 
female, male, or transgender female/male partners; receptive intercourse was defined as 
receptive anal intercourse with male or transgender male partners. 
 
Analysis of HIV tropism 
 HIV tropism testing was performed retrospectively using samples from two 
groups of men: (1) men who were HIV infected at enrollment and reported either 
exclusive insertive intercourse or exclusive receptive intercourse in the previous six 
months, and (2) men who seroconverted during the study. All samples tested had a viral 
load ≥1,000 copies/mL.  
 
Statistical methods 
Correlates of HIV tropism were analyzed using Fisher’s exact and chi-square 
tests for univariate analyses. SAS, version 9.2 (SAS Institute, Cary, NC) was used for 





 In HPTN 061, 147 (42%) of the 348 men who were HIV-infected at enrollment 
had a viral load ≥1,000 copies/mL. HIV tropism was analyzed in samples from 51 of 
those men: 32 (63%) reported exclusive insertive intercourse and 19 (37%) reported 
exclusive receptive anal intercourse. Samples from the first HIV-positive visit were also 
analyzed for 21 (75%) of the 28 men who seroconverted during HPTN 061; the 
remaining seven men included six who had viral loads <1,000 copies/mL at the first HIV-
positive visit [54] and one who had no sample available for testing. HIV tropism was 
determined for 63 of the 72 samples (Table 4.1). HIV tropism was not determined for 
nine samples due to assay failure, including samples from five men who reported 
exclusive insertive intercourse, three who reported exclusive receptive intercourse, and 
one seroconverter. 
DM viruses were detected in 11 (26%) of 43 men who were HIV infected at 
enrollment, including eight (30%) of 27 men who reported exclusive insertive intercourse 
and three (19%) of 16 men who reported exclusive receptive intercourse (P=0.49; data 
not shown). DM viruses were also detected in 5 (25%) of 20 seroconverters. Since the 
proportion of men with DM viruses was similar among the HIV-infected men at 
enrollment and the seroconverters, these groups were combined to analyze factors 
associated with detection of DM viruses (Tables 4.1 and 4.2). Overall, men who had DM 
viruses had lower median CD4 cell counts compared to men who had R5 viruses (184 
cells/mm3 vs. 386 cells/mm3; P=0.019; Table 4.1); all five seroconverters who had DM 
viruses had CD4 cell counts <350 cells/mm3 (Table 4.3). None of the other factors 
evaluated was associated with detection of DM viruses in this study. 
Individual env clones from the five seroconverters who had DM viruses were 
analyzed to determine whether their viral populations were comprised solely of dual-
tropic viruses or mixtures of R5, X4, and dual-tropic viruses (Table 4.3). Dual-tropic 
39 
 
viruses were further classified as either dual-R or dual-X in these analyses [46, 86]. 
Dual-R viruses infect CXCR4+ cells poorly and have env V3 loop sequences similar or 
identical to R5 viruses from the same individual, while dual-X viruses infect CXCR4+ 
cells efficiently and have env V3 loop sequences distinct from R5 viruses from the same 
individual.  
Mixed populations of R5 and dual-R viruses were detected in two of the five men 
(Cases 1 and 2, Table 4.3). There was a major subpopulation of dual-R viruses in Case 
1, which had V3 sequences identical to those in one R5 clone. In Case 2, there were two 
proportionate subpopulations of R5 and dual-R viruses, which had identical V3 
sequences. Dual-X viruses were detected in the remaining three men (Cases 3-5). All 
clones from Cases 3 and 4 were dual-X and had identical (Case 3) or nearly identical 
(Case 4) V3 sequences. The viral population in Case 5 included a major subpopulation 
of R5 and minor subpopulations of dual-X viruses. 
 
Discussion 
 This study explored whether sexual practices were associated with HIV tropism 
among HIV-infected men enrolled in HPTN 061. A significant difference in HIV tropism 
was not observed among men who reported exclusive insertive vs. receptive intercourse 
at study enrollment. The sexual practices of the men included in this analysis may have 
been different at the time of HIV infection than those reported for the six months 
preceding enrollment; self-report of sexual practices may also be unreliable in some 
cases. In addition, HIV evolution and superinfection could also impact the tropism of the 
viral population over time. Overall, DM viruses were detected among 26% of the HIV-
infected men at enrollment, which is consistent with other studies that found X4/DM 
viruses in 20% of individuals with chronic HIV infection [77]. 
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Twenty-five percent of the seroconverters in HPTN 061 also had DM viruses. In 
other studies, X4/DM viruses have been observed in 2-20% of individuals with recent 
HIV infection [77, 79-81]. It is difficult to compare the proportion of individuals with 
X4/DM viruses in different studies, since the sensitivity for detecting X4/DM viruses 
depends on the method used for tropism testing. In this study, HIV tropism was 
determined using a clinically-validated, phenotypic tropism assay with enhanced 
sensitivity (Trofile), which can detect X4/DM variants present in 0.3% of the viral 
population [44]. Most genotypic tropism assays use bulk (population) Sanger 
sequencing; these methods typically detect minority variants present at 15-20% [87]. 
The sensitivity and specificity of genotypic tropism assays varies depending on the 
algorithms and cut-offs used to analyze V3 loop sequences [87]. Determinants outside 
the V3 loop may also impact HIV tropism [46, 88]. Those regions are included in the 
recombinant viruses analyzed in the Trofile assay but not in genotypic tropism assays. In 
two of the five seroconverters in this study, dual-tropic env clones were identified that 
had V3 loop sequences identical to those in R5-tropic clones from the same samples; 
HIV tropism would have been misclassified in these cases using a genotypic assay 
based on env V3 sequencing. 
In HPTN 061, men with DM viruses had significantly lower CD4 cell counts, 
consistent with findings from other studies [77]. The five seroconverters with DM viruses 
also had low CD4 cell counts (median: 254 cells/mm3, range: 151-335 cells/mm3). Other 
studies did not find a significant difference in CD4 cell count between individuals with 
X4/DM vs. R5 viruses early in infection [78, 83, 89], although those with X4/DM viruses 
had more pronounced CD4 cell count decline over time in two of those studies [78, 83]. 
In another study, a lower mean CD4 cell count was observed among seroconverters with 
DM vs. R5 viruses (450 vs. 629 cells/mm3) [81]. Low CD4 cell counts after 
seroconversion have been associated with faster HIV disease progression, independent 
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of HIV tropism [90, 91]. In addition, individuals starting ART with CD4 cell counts <500 
cells/mm3 may not achieve the same degree of CD4 cell count recovery as those starting 
ART at higher CD4+ cell counts [92]. 
 The CCR5 coreceptor antagonist, maraviroc, is currently approved for ART in the 
US [14], and clinical trials are exploring its use for PrEP [84, 85]. Coreceptor tropism 
testing is recommended before using maraviroc for ART, since maraviroc may select for 
X4 and dual-tropic viruses [35]. In HPTN 061, the seroconverters with DM viruses had 
viral populations that included either dual-tropic viruses or mixtures of R5 and dual-tropic 
viruses; the efficiency of CXCR4 use varied among the dual-tropic clones from each 
individual. The relatively high prevalence of DM viruses among Black MSM in HPTN 061 
with both prevalent and incident HIV infection suggests that maraviroc may not be a 
suitable PrEP agent in this population. 
 Black MSM in the US are disproportionately affected by HIV. Infrequent HIV 
testing prior to enrollment and late HIV diagnosis were common in the HPTN 061 cohort 
[93]. X4/DM viruses have been associated with increases in viral load, more rapid CD4 
cell decline, and faster disease progression [77, 78]. The high prevalence of X4/DM 
viruses among men in HPTN 061 highlights an urgent need to increase HIV testing 
frequency in this population. Further research is also needed to identify factors driving 
transmission and selection of X4/DM viruses and to evaluate potential associations of 





Table 4.1. Association between HIV tropism and demographic and clinical factors. 
  Total DM R5  
Characteristic  63 16 47 P value 
City Atlanta 12 (19%) 3 (19%) 9 (19%) 0.26 
 Boston 5 (8%) 1 (6%) 4 (9%)  
 Los Angeles 24 (38%) 7 (44%) 17 (36%)  
 New York City 9 (14%) 1 (6%) 8 (17%)  
 San Francisco 7 (11%) 4 (25%) 3 (6%)  
 Washington, DC 6 (10%) 0 (0%) 6 (13%)  
Age ≤30 years 27 (43%) 7 (44%) 20 (43%) 0.93 
 >30 years 36 (57%) 9 (56%) 27 (57%)  
Sexual identity Homosexual/gay 30 (48%) 9 (56%) 21 (45%) 0.76 
 Bisexual 16 (25%) 3 (19%) 13 (28%)  
 Other 17 (27%) 4 (25%) 13 (28%)  
Education High school or less 34 (54%) 9 (56%) 25 (53%) 0.83 
 At least some college 29 (46%) 7 (44%) 22 (47%)  
Household income ≤$30,000/year 51 (81%) 12 (75%) 39 (83%) 0.48 
 >$30,000/year 12 (19%) 4 (25%) 8 (17%)  
Employment status Employed 15 (24%) 5 (31%) 10 (21%) 0.50 
 Unemployed 48 (76%) 11 (69%) 37 (79%)  
Student status Student 18 (29%) 5 (31%) 13 (28%) 0.76 
 Non-student 45 (71%) 11 (69%) 34 (72%)  
Circumcision status Circumcised 51 (81%) 13 (81%) 38 (81%) 1.00 
 Uncircumcised 12 (19%) 3 (19%) 9 (19%)  
STI at enrollment Yes 13 (21%) 2 (13%) 11 (23%) 0.49 
 No 50 (79%) 14 (88%) 36 (77%)  
Median viral load (copies/mL)  22,551 56,152 20,236 0.28 





Legend for Table 4.1. 




Table 4.2. Association between HIV tropism and behavioral factors. 
  Total DM R5  
Characteristic  63 16 47 P value 
Number of male partners 0-1  13 (21%) 5 (31%) 8 (17%) 0.29 
 >1 50 (79%) 11 (69%) 39 (83%)  
Gender of partners Male only 42 (67%) 9 (56%) 33 (70%) 0.31 
 Male and female 21 (33%) 7 (44%) 14 (30%)  
Had a new male partner Yes 51 (81%) 11 (69%) 40 (85%) 0.16 
 No 12 (19%) 5 (31%) 7 (15%)  
Race/ethnicity of partners All Black 41 (65%) 10 (63%) 31 (66%) 0.89 
 Some Black 18 (29%) 5 (31%) 13 (28%)  
 None Black 4 (6%) 1 (6%) 3 (6%)  
Unprotected receptive anal 
intercourse 
Yes 31 (49%) 6 (38%) 25 (53%) 0.28 
 No 32 (51%) 10 (63%) 22 (47%)  
Unprotected insertive anal 
intercourse 
Yes 30 (48%) 8 (50%) 22 (47%) 0.83 
 No 33 (52%) 8 (50%) 25 (53%)  
Received money/goods for sex Yes 13 (21%) 3 (19%) 10 (21%) 1.00 
 No 50 (79%) 13 (81%) 37 (79%)  
Provided money/goods for sex Yes 7 (11%) 1 (6%) 6 (13%) 0.67 
 No 56 (89%) 15 (94%) 41 (87%)  
Alcohol problema Yes 14 (22%) 4 (25%) 10 (21%) 0.74 
 No 49 (78%) 12 (75%) 37 (79%)  
Substance useb Yes 41 (65%) 11 (69%) 30 (64%) 0.72 





Legend for Table 4.2. 
Men were asked to report behaviors in the six months prior to enrollment. P values <0.05 are bolded. Abbreviations: DM: dual/mixed 
viruses; R5: CCR5-using viruses. 
a Alcohol use was defined as having a score ≥8 using the Alcohol Use Disorders Identification Test. 
b Substance use included inhaled nitrates, smoked and powder cocaine, methamphetamine, heroin, nonprescription drug use 
(Oxycontin, Vicodin, or Xanax), or any other hallucinogens. Injection drug use was reported in only four (6%) of 63 men included in 
this analysis. This included three men who were HIV infected at enrollment (two with R5 viruses and one with DM viruses) and one 

















V3 loop amino acid sequences 
1 242,022 334 9 Dual-R 57,874-381,187 1,160-28,202 CTRPNNNTRKSIHIAPGRAFFATGDIIGDIRQAHC 
   2 R5 53,141-91,918 57-72 ............N.......Y....M......... 
 
  2 Dual-R 92,523-179,041 8,182-15,549 ....................Y.............. 
  1 R5 57,634 69 ............N.......Y.............. 
 
  1 R5 56,344 65 ....................Y.............. 
 
  1 R5 20,159 71 ................................... 
 
  1 Dual-R 202,966 1,525 .A................................. 
 
  1 Dual-R 191,955 11,286 .............V..................... 
 
  1 Dual-R 153,724 3,106 .................K..Y.............. 
 
  1 Dual-R 109,342 1,496 .............M..................... 
2 141,411 254 8 Dual-R 50,401-229,518 302-2,472 CTRPGNNTRKSIHIGPGRAFYATGDIIGDIRQAHC 
   6 R5 33,694-131,674 50-103 ................................... 
 
  1 R5 38,299 79 .A................................. 
 
  1 Dual-R 229,518 2,014 .............M..................... 
3 90,920 335 18 Dual-X 494-211,474 96,584-1,451,417 CTRPNNNTRKRMSLGPGKVFYTTGGIIGDIRKAHC 
4 165,010 235 10 Dual-X 1,804-19,776 16,153-87,607 CTRPNNNTRKSIRIGPGRWSVFATGKIIGDIRQAHC 
 
  3 Dual-X 1,783-4,628 15,345-35,774 ........................E.......R... 
 
  2 Dual-X 3,011-31,528 38,768-128,306 ................................R... 
 
  1 Dual-X 2,163 16,759 ......................T............. 
5 79,450 151 11 R5 30,379-154,907 55-99 CSRPNNNTRKSISIGPGRAFYATGDIIGDIRQAHC 
 
  2 Dual-X 49,924-65,980 396,970-629,351 ..........G.R.....T.....R.......... 
 
  2 Dual-X 8,888-19,161 86,732-185,976 ............R.....T.....R.......... 
 





Legend for Table 4.3. 
Amino acid positions 11 and 25 in the env V3 loop are underlined. Abbreviations: no.: number; RLU: relative light units of luciferase 
output from the Trofile assay; R5: CCR5-using viruses. 
a Viral load was measured as copies/mL. 
b CD4 cell count was measured as cells/mm3. 
c The total number of clones in each individual with the indicated V3 loop sequence. 
d HIV tropism for each env clone was determined using the Trofile Assay. Clones were identified as CCR5-using (R5), CXCR4-using 
(X4), or dual-tropic virus. Dual-tropic viruses were further classified as dual-R or dual-X according to their CXCR4+ cell infectivity 
and V3 loop sequence. 

















The high genetic diversity of HIV complicates the use of ARV drugs for PrEP, 
PEP, and ART and has hindered the development of a HIV vaccine [94, 95]. HIV 
diversity tends to be low early in infection, since only one or a few HIV variants typically 
establish infection. Rapid HIV diversification occurs after infection as the result of 
numerous host and viral factors [17]. Traditionally, HIV diversity is measured by 
sequencing clones from individual HIV variants, or by sequencing individual variants 
using single genome sequencing or next generation sequencing; these methods are 
time consuming and costly, which may limit study size and the number of genomic 
regions analyzed. The HRM diversity assay quantifies viral diversity without sequencing. 
The assay uses a nested PCR to amplify HIV DNA in the presence of a fluorescent, 
intercalating, duplex-dependent dye [47]. The melting range of the resulting DNA 
amplicons (i.e., the number of degrees over which melting occurs) is measured as a 
single numeric HRM score [47, 50]. HRM scores are significantly correlated with 
sequence-based diversity measures, including genetic diversity, genetic complexity, and 
Shannon entropy [47, 49]. 
The HRM diversity assay has been used to measure HIV diversity in adults with 
recent and established infection and in HIV-infected infants and children [29, 48, 96, 97]. 
Higher HRM scores (i.e., higher levels of diversity) were observed in adults with a longer 
duration of HIV infection [48, 96] and in older children, where age acts as a surrogate for 
the duration of infection [29, 97]. HIV diversity may also impact disease progression and 
ART outcome. Higher HRM scores in the HIV gag and pol regions were associated with 
decreased 5-year survival in children [97], and lower HRM scores were observed in 
children who experienced prolonged exposure to non-suppressive ART (i.e., genetic 
bottlenecking) [29]. Better ART outcomes, including shorter time to virologic suppression 
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and longer time to virologic failure, were associated with higher HRM scores in the HIV 
pol region in African children [98]. 
In this study, the HRM diversity assay was used to evaluate the relationship 





 The HRM diversity assay used to characterize HIV in samples from HIV-infected 
men in HPTN 061 who had viral loads >400 copies/mL; this included men who were HIV 
infected at enrollment and men who seroconverted during the study. 
 
Laboratory and statistical methods 
 Six regions of the HIV genome were analyzed in this study using the HRM 
diversity assay: two in gag (GAG1 and GAG2), one in pol (POL), and three in env 
(ENV1, ENV2, and ENV3; see Chapter 2). Median regression analyses were used to 
evaluate associations between HRM scores and demographic and clinical 
characteristics for each HRM region; P values <0.05 was considered statistically 
significant. For men who were HIV infected at enrollment, multiple median regressions 
were performed for multivariate analyses of variables that were significantly associated 
with HRM score at the P<0.05 level in univariate analyses. Wilcoxon signed-rank tests 
were used to analyze the change in HRM score from enrollment to end of study in a 
paired analysis. Associations between change in HRM score and demographic and 







In HPTN 061, 348 men were HIV infected at study enrollment. The HRM diversity 
assay was performed for 168 (48%) of the men (Figure 5.1); these men had enrollment 
samples available for additional testing with a viral load >400 copies/mL. The HRM 
diversity assay was also performed for 23 (82%) of 28 men who seroconverted during 
the HPTN 061 study; the remaining five men included four who had viral loads <400 
copies/mL at the first HIV-positive visit [54] and one who had no sample available for 
testing. HRM scores for all six regions were obtained for 146 (87%) of the 168 men who 
were HIV infected at enrollment and 21 (91%) of 23 seroconverters. A summary of 
demographic and clinical characteristics for the men included in the following analyses is 
shown in Table 5.1. 
  
Association of HIV diversity with recent HIV infection 
 The association between HRM scores and recent HIV infection was first 
assessed; this assessment included men who were acutely or recently infected at 
enrollment and seroconverters (Table 5.1). The 146 men who were HIV infected at 
enrollment included 3 with acute HIV infection and 13 with recent HIV infection 
(classified using a MAA [37], see Chapter 2); men classified as recently infected by the 
MAA were likely infected in the 6 months prior to study enrollment. The remaining 130 
men who were HIV infected at enrollment were classified as having non-recent infection 
(Table 5.1). The seroconverters in HPTN 061 were infected within 6 months of their first 
HIV positive visit (i.e., time since their last documented seronegative study visit). 
 Since the seroconverters had a known time window of infection, HRM scores 
were first compared between seroconverters and men who had non-recent infection at 
enrollment. In univariate analyses, HRM scores were significantly lower in all six HRM 
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regions for seroconverters than for men with non-recent infection (P=0.003 for ENV2, 
P<0.0001 for the other regions, Figure 5.2A). Similarly, HRM scores were significantly 
lower in all six regions for men who had acute or recent infection at enrollment than for 
men with non-recent infection (P<0.0001 for all, Figure 5.2B). In multivariate analyses, 
HRM scores remained significantly lower for men with acute or recent infection at 
enrollment, when the analysis was adjusted for other variables (P=0.009 for GAG2, 
P<0.0001 for the other regions, Table 5.3). 
 
Association of HIV diversity with demographic and clinical characteristics 
 The association between HRM scores and additional demographic and clinical 
characteristics was analyzed for men who were HIV infected at enrollment (Table 5.2); 
meaningful statistical analyses could not be performed for seroconverters, due to the 
small number of participants. In univariate analyses, HRM scores were significantly 
lower in one or more HRM region for men who were younger (≤30 years, Figure 5.2C), 
had HIV drug resistance (Figure 5.2D), had an ARV drug detected, or had higher CD4 
cell counts (Figure 5.3). In multivariate analyses, HRM scores remained significantly 
lower for men who were younger (ENV1), had HIV drug resistance (GAG1 and GAG2), 
or had higher CD4 cell counts (GAG2); these results are shown in Table 5.3. 
 
Analysis of HIV diversification over 12 months 
 In HPTN 061, men were followed for 12 months. HIV diversification during follow-
up was evaluated using samples from men who were HIV infected at enrollment and had 
an end-of-study sample available for analysis. Fifty-two (36%) of the 146 men who had 
HRM scores at enrollment were lost to study follow-up and could not be analyzed 
(Figure 5.1). The HRM diversity assay was performed using end-of-study samples from 
70 (48%) of the 146 men. HRM scores were obtained for all six regions for 62 (89%) of 
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the 70 men at the last study visit. The change in HRM score was calculated by 
subtracting the HRM score at enrollment from the HRM score at follow-up for all six 
HRM regions. HRM scores significantly increased over time for GAG1 and POL (P=0.03 
and P<0.0001, respectively). In univariate analyses, POL HRM scores increased more 
among men who had acute or recent infection (P=0.03, Figure 5.4), lower HIV viral loads 
(P=0.02), and higher CD4 cell counts (P=0.03). In addition, ENV3 HRM scores 
decreased for men who had ARV drugs detected (P=0.049). 
 
Discussion 
 In this study, HIV diversity was analyzed in six regions in HIV gag, pol, and env 
among HIV-infected men enrolled in HPTN 061. As expected, HIV diversity was lower 
overall among seroconverters and men with acute or recent HIV infection compared to 
men with non-recent HIV infection. Men with recent and non-recent HIV infection in 
HPTN 061 were classified using a MAA designed for cross-sectional incidence surveys 
[37]. The MAA used in this study included two serologic and two non-serologic 
biomarkers. The lower HIV diversity observed among men classified as recently infected 
at enrollment provides additional confirmation that the MAA accurately identifies 
individuals who recently acquired HIV infection. 
 After adjusting for acute or recent infection, HIV diversity at study enrollment was 
significantly lower in the GAG2 region among men with higher CD4 cell counts. This is 
consistent with a previous study of Kenyan women where lower gag diversity was 
strongly correlated with higher CD4 cell count during chronic HIV infection [99]. HIV 
diversity was also lower in the ENV1 region for younger men (<30 years) in this study. 
Collectively, these findings may reflect the evolution of the host adaptive immune 
response to HIV. Immune pressure from cytotoxic T lymphocyte (CTL) and antibody 
responses can impact HIV diversity in gag and env, respectively [99, 100]. It is possible 
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that the men with lower HIV diversity in the GAG2 and ENV1 regions had a shorter 
duration of infection and therefore, a less evolved immune response. CD4 cell counts 
are generally higher early in infection [101], and younger age was associated with HIV 
acquisition in HPTN 061 [10]. 
 Lower HIV diversity in both gag regions was also associated with having HIV 
drug resistance to NRTIs, NNRTIs, and PIs. This finding is unusual since these ARV 
drug classes target enzymes encoded by HIV pol (protease and reverse transcriptase). 
In a previous study, prolonged exposure to non-suppressive ART was significantly 
associated with decreases in HIV diversity in gag, pol, and env (i.e., genetic 
bottlenecking) in Ugandan children [29]. Lower diversity in the GAG2 region was also 
associated with self-reported prior maternal ARV drug use in a cohort of African children 
[98]. These findings suggest that the selective pressure exerted by ARV drug use may 
also influence HIV diversity in untargeted regions. There was no association between 
HIV diversity and ARV drug detection in this study. The ARV drug assay used in this 
dissertation can only detect drugs taken recently. It is possible that the men who had 
ARV drugs detected did not experience a prolonged exposure to non-suppressive ARV 
drug levels (e.g., men may have only recently initiated or failed ART). Half of the men 
who had ARV drugs detected in HPTN 061 did not have HIV drug resistance (see 
Chapter 4). In this case, HIV drug resistance may more accurately reflect extended non-
suppressive ARV drug use. 
 This study also analyzed HIV diversification over 12 months in a subset of men 
who had samples available at the end of the HPTN 061 study. HIV diversity increased in 
all six genomic regions analyzed for men with acute or recent infection. However, there 
was no significant difference in HIV diversification when compared to men with non-
recent infection, except in the POL region. It is not clear why the HIV pol region 
diversified more in men with acute or recent infection. In one study, HIV diversity in gag 
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and env, but not pol, significantly increased for African women with recent infection 
compared to women with known non-recent infection (duration of infection: two to six 
years) [96]. Those findings are consistent with HIV diversification in response to the 
adaptive immune response, which targets HIV epitopes in gag and env [99, 100]. HIV 
epitopes in pol can also be targeted by the adaptive CTL response [102]. In HPTN 061, 
HIV pol also diversified more in men with lower HIV viral loads and men with higher CD4 
cell counts in HPTN 061. These increases in HIV diversity may reflect a more robust 
immune response in these individuals. The CTL response contributes to establishing 
HIV viral load setpoint after acute HIV infection [103], while CD4+ T cells play a central 
role in antibody development. 
 Understanding factors associated with HIV diversification may yield new insights 
into the selective pressures driving viral evolution. The HRM diversity assay used in this 
study can analyze multiple genomic regions to provide a more complete picture of HIV 
diversification in response to these pressures. Additional studies are needed to explore 






Table 5.1. Summary of study participants. 
  Median (IQR) 
Subset Total Age (years) 
HIV viral load 
(log10) 
CD4 cell count 
(cells/mm3) 
HIV infected at enrollment 146 39 (28, 45) 4.36 (3.75, 4.82) 356 (196, 519) 
Acute or recent infections 16 25 (20,36) 4.64 (4.24, 5.29) 525 (381, 804) 
Non-recent infections 130 41 (31, 46) 4.32 (3.73, 4.81) 321 (193, 499) 
HIV seroconverters 21 23 (20, 28) 4.90 (4.29, 5.22) 576 (324, 707) 
 
Legend for Table 5.1. 
Abbreviations: IQR: interquartile range.  
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Table 5.2. Association of HIV diversity with clinical and demographic factors at study 
enrollment (univariate analyses). 
Characteristic GAG1 GAG2 POL ENV1 ENV2 ENV3 
Acute or recent infection <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Age (years) 0.049 0.031 0.333 0.002 0.380 0.144 
HIV drug resistance 0.110 0.023 0.145 1.000 0.755 0.028 
ARV drug detected 0.520 0.351 0.047 1.000 1.000 0.086 
STI 0.820 0.795 0.577 0.160 0.575 0.736 
HIV viral load (log10) 0.163 0.534 0.341 0.417 0.793 1.000 
CD4 cell count (cells/mm3) 0.426 0.040 0.054 0.031 <0.0001 0.050 
 
Legend for Table 5.2. 





Table 5.3. Multivariate analyses of HIV diversity at study enrollment. 
Covariate Region Estimatea 95% CI P value 
Acute or recent infection GAG1 -1.11 -1.51, -0.70 <0.0001 
 GAG2 -1.46 -2.54, -0.37 0.009 
 POL -1.08 -1.42, -0.73 <0.0001 
 ENV1 -0.90 -1.18, -0.61 <0.0001 
 ENV2 -1.25 -1.85, -0.66 <0.0001 
 ENV3 -1.90 -2.76, -1.05 <0.0001 
Age ≤30 years GAG1 0.05 -0.43, 0.52 0.85 
 GAG2 -1.06 -2.13, 0.01 0.05 
 POL -0.23 -0.55, 0.08 0.15 
 ENV1 -0.29 -0.57, -0.005 0.046 
 ENV2 -0.07 -0.64, 0.50 0.81 
 ENV3 -0.39 -1.24, 0.46 0.37 
HIV drug resistance GAG1 -0.54 -0.99, -0.10 0.017 
 GAG2 -1.69 -2.57, -0.80 0.0003 
 POL -0.19 -0.55, 0.17 0.29 
 ENV1 -0.08 -0.38, 0.23 0.61 
 ENV2 -0.31 -0.87, 0.26 0.28 
 ENV3 -0.70 -1.49, 0.10 0.09 
ARV drug detected GAG1 -0.14 -0.56, 0.28 0.50 
 GAG2 -0.13 -0.96, 0.70 0.76 
 POL -0.04 -0.36, 0.28 0.80 
 ENV1 0.09 -0.19, 0.36 0.53 
 ENV2 0.19 -0.32, 0.70 0.47 
 ENV3 -0.10 -0.85, 0.65 0.80 
CD4 cell count GAG1 -0.0002 -0.0012, 0.0008 0.71 
 GAG2 -0.0009 -0.0018, 0.00 0.049 
 POL -0.0002 -0.0007, 0.0003 0.45 
 ENV1 -0.0001 -0.0007, 0.0005 0.66 
 ENV2 -0.0007 -0.0014, 0.0001 0.096 
 ENV3 -0.0004 -0.0017, 0.0008 0.49 
 
Legend for Table 5.3. 
P values <0.05 are bolded. Abbreviations: CI: confidence interval. 
a The estimate shows the difference in median HRM score for each factor after adjusting 




Figure 5.1. Study cohort. 
 
Legend for Figure 5.1. 
The high resolution melting (HRM) diversity assay was used to analyze samples from 
men who were HIV infected at enrollment, had a sample available for additional testing, 
and had a viral load >400 copies/mL. Men who had HRM scores for all six regions 
analyzed were included in analyses of HIV diversity at enrollment and in analyses of HIV 









Legend for Figure 5.2. 
Box and whisker plots show the distribution of high resolution melting (HRM) scores for all six regions analyzed for HIV 
seroconverters (A) and men who were HIV infected at study enrollment (A-D). For each column, the mean (circle), median (inner 
line), interquartile range (box), lower inner and upper outer fences (whiskers), and outliers are shown. Men who were HIV infected at 
enrollment were classified as having recent or non-recent HIV infection using a MAA. Univariate median regression analyses were 
used to compare HRM scores between the indicated groups; P values for these comparisons are shown (*P<0.05; **P<0.01).  
 
 
Figure 5.3. Association of HIV diversity and CD4 cell count in men who were HIV 
infected at enrollment. 
 
 
Legend for Figure 5.3. 
Scatterplots show the relationship between high resolution melting (HRM) score and 




Figure 5.4. Association between change in HRM score with HIV infection stage (paired 
analysis). 
 
Legend for Figure 5.4. 
Box and whisker plots show changes in HRM score over 12 months for men by HIV 
infection stage (acute or recent vs. non-recent). For each column, the mean (circle), 
median (inner line), interquartile range (box), lower inner and upper outer fences 
(whiskers), and outliers are shown. The change in HRM score was calculated by 
subtracting HRM scores obtained for the enrollment visit from those obtained for the 12-















 The HPTN 061 study provided key insights into the HIV epidemic among Black 
MSM in the US. The men enrolled in HPTN 061 were all at a high risk for HIV 
transmission or acquisition. The two groups most at risk for transmitting HIV in HPTN 
061 were analyzed in these studies: HIV-infected men who were not virally suppressed 
at enrollment and HIV seroconverters. Maintaining viral suppression in HIV-infected 
individuals on ART is crucial to improving health outcomes and preventing onward HIV 
transmission [104, 105]. To achieve viral suppression, individuals must first know they 
are infected, engage in HIV care, and then be prescribed and adhere to ART [106]. The 
work in this dissertation revealed pressing concerns about the availability and quality of 
HIV care for Black MSM at each of these stages in the HIV care continuum. 
 
HIV treatment 
Approximately half of the HIV-infected men in HPTN 061 were not virally 
suppressed at the time of study enrollment; this included men who were newly 
diagnosed, previously diagnosed but not in HIV care, and previously diagnosed and in 
HIV care. Many of these men had HIV drug resistance to NRTIs, NNRTIs, and PIs; 11% 
had MCR to two or more of those ARV drug classes. NNRTI and PI resistance was also 
detected in nearly a quarter of newly-infected men, including men with acute or recent 
infection at enrollment and men who seroconverted during the study. Notably, none of 
the men in HPTN 061 had INSTI resistance. This is promising since current first-line 
ART regimens in the US are comprised of two NRTIs (abacavir/3TC or FTC/TFV) with 
either an INSTI or RTV-boosted PI [51]. Unlike NNRTIs and INSTIs [107-109], NRTIs 
still possess partial ARV activity despite the presence of NRTI-associated DRMs [110]. 
Therefore, although NRTI resistance was common in HPTN 061, the men with drug-
resistant HIV may still be able to take an INSTI-based ART regimen. 
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A third of the men who were not virally suppressed also had ARV drugs detected; 
these men were at risk for developing additional HIV drug resistance. Both HIV drug 
resistance and ARV drug detection were associated with self-reporting previous or 
current ART, which suggests some engagement in HIV care. However, ARV drug 
detection was not associated with self-reporting being in HIV care. It is possible that the 
men who had ARV drugs detected and reported current ART had recently initiated 
treatment and had not yet achieved viral suppression. However, it is not clear why men 
who reported previous but not current ART had ARV drugs detected; these men may 
have been previously engaged but not retained in HIV care. Many men also had unusual 
patterns of ARV drugs detected that were not recommended for ART [51-53]. Together, 
these findings suggest that men in HPTN 061 were taking ARV drugs without medical 
supervision for ART or other reasons. Additional studies are needed to understand the 
quality of HIV care and loss to ART follow-up for Black MSM as well as how they acquire 
and use ARV drugs. 
 
HIV prevention 
PrEP uptake among Black MSM has the potential to decrease HIV incidence in 
this population. Currently, Truvada® (FTC/TFV disoproxil fumarate) is the only ARV drug 
combination approved by the US FDA for PrEP [24]. In HPTN 061, the second most 
common DRM detected was M184V/I, which confers HIV drug resistance to FTC but 
increases HIV susceptibility to TFV. It is unclear whether drug-resistant viruses with the 
M184V/I mutation would impact PrEP efficacy. Transmission of drug-resistant HIV to an 
individual taking PrEP has been documented [111]. The drug-resistant variant in this 
case had MCR to NRTIs, NNRTIs, and INSTIs; notably, numerous NRTI-associated 
resistance mutations in addition to M184V were detected. As PrEP uptake continues to 
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increase, careful monitoring of prevalent as well as transmitted HIV drug resistance is 
needed in at-risk populations. 
 Several ARV drugs are also being evaluated as potential PrEP agents, including 
maraviroc, rilpivirine, and cabotegravir. Maraviroc-based regimens for PrEP were shown 
to be promising in phase II studies in MSM in the US [85]. However, DM viruses were 
frequently detected among the HIV seroconverters in HPTN 061; therefore, maraviroc-
based regimens may not be appropriate for PrEP among Black MSM at a high risk for 
HIV acquisition. The NNRTI rilpivirine and the INSTI cabotegravir are under 
consideration as long-acting injectable forms of PrEP that can be administered every few 
months [75, 76]. Rilpivirine resistance was predicted in two men in HPTN 061 at 
enrollment; both men had MCR. In contrast, INSTI resistance was not predicted for any 
of the men in HPTN 061, including seroconverters. These findings are promising if 
clinical studies can demonstrate the efficacy of long-acting rilpivirine and cabotegravir for 
PrEP. Routine HIV drug resistance surveillance among Black MSM in the US will be 
needed as rilpivirine and INSTI use for ART continues to increase. 
 
HIV diagnosis 
As PrEP uptake continues to increase, studies are needed to characterize new 
HIV infections that may occur in individuals who take PrEP. Macaques that acquire 
simian immunodeficiency virus infection while taking ARV drugs for PrEP or PEP can 
experience an attenuated course of infection [112, 113]. Attenuated infection has also 
been observed in a case study of a clinical patient who acquired HIV infection while 
taking PEP [114]. In HPTN 061, ARV drugs were detected in one man with acute HIV 
infection and nine men with recent HIV infection at enrollment, which suggests that ARV 
drug use occurred among men who likely thought they were HIV uninfected. None of the 
HIV seroconverters had ARV drugs detected at their first HIV-positive visit. However, a 
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separate study revealed that one man had DRV and tipranavir detected at enrollment 
(i.e., while he was HIV uninfected) [54]. In that study, six (21%) of the 28 HIV 
seroconverters in HPTN 061 who had low or undetectable levels of HIV RNA at their first 
HIV-positive visit were characterized [54]. It is possible that ARV drug use at or near the 
time of HIV acquisition contributed to the unusual prevalence of low or undetectable 
viremia observed among these men. Two seroconverters who had undetectable viral 
loads were missed by several HIV tests, including fourth-generation assays [54], which 
suggests that such scenarios may complicate HIV diagnoses. 
Infrequent HIV testing and late diagnoses were common in HPTN 061 [93]. It is 
possible that the HIV-infected men who received false-negative HIV test results would 
not have retested for HIV within 12 months if they had not been enrolled in the study. 
Viral load rebounds can occur in individuals with low or undetectable HIV RNA [115-
117], which would increase their risk for HIV transmission. Diagnosing and engaging 
such individuals in care is important so their viral loads can be monitored. A quarter of 
the HIV seroconverters in HPTN 061 also had DM viruses and CD4 cell counts <350 
cells/mm3. DM viruses and low CD4 cell counts are both associated with accelerated 
disease progression [77, 78, 90, 91]. Diagnosing these men soon after HIV infection 
would facilitate earlier ART initiation, which can lead to better health outcomes [118, 
119]. These findings further highlight the urgency of expanding HIV testing efforts among 
Black MSM.  
 
Future directions 
 Additional studies are needed to understand the unusual patterns of ARV drug 
use among both HIV-infected and HIV-uninfected Black MSM. ARV drug testing could 
not be performed for the HIV-uninfected men enrolled in HPTN 061. However, in a 
separate study, ARV drugs were detected in 39 samples from HIV-uninfected women at 
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a high risk for HIV infection in the US [120]. Multiple PIs and outdated PIs were detected 
among these women, which was similar to that observed in HPTN 061. ARV drug testing 
in future cohorts of HIV-uninfected Black MSM may provide additional insight into the 
patterns of and motivations for ARV drug use in this population. 
Interventions designed to increase HIV awareness, prevention, and detection are 
urgently needed to control the HIV epidemic among Black MSM in the US. These 
interventions must expand the availability and quality of health services for diagnosing 
and treating HIV in this population and ensure that these health services are acceptable 
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